Tempus AI (TEM) shares fell sharply by 5.87% during intraday trading on Tuesday, following a significant target price reduction by a major financial institution.
The decline came after Morgan Stanley cut its price target for Tempus AI to $70.00 from $85.00, representing a substantial downward revision in the bank's valuation of the company.
While Tempus AI also announced a strategic, multi-year collaboration with Merck to accelerate AI-driven precision medicine, the negative impact of the analyst target price cut appears to have outweighed the positive collaboration news in today's trading session.